blood taken from the same subject were evaluated. We chose to assay serum because it yielded higher PTH results than EDTA plasma or whole blood in our method. The PTH beads from the kit were placed in a 20-place wide-well plate. The kit calibrators, controls, and both of the patient's specimens (pre-and postexcision) were all set up in duplicate except for the two highest-concentration calibrators, which we used in singlicate to allow the entire assay to fit on one plate. The kit isotope was added, and the plate was covered and placed in an Abbott Dynamic Incubator for 10 mm at 45 #{176}C in a rotating mode. The liquid was then aspirated and the beads were transferred to test tubes by utilizing the Abbott transfer system for EIA quantum technology. After washing the beads twice and removing the liquid by aspiration, we placed the tubes containing the beads in a gamma counter and counted the radioactivity for 1 mm.
We Enrolled in the study with their informed written consent were 2 I hospitalized patients (17 males and 4 females) with head and neck tumors, all of whom were undergoing concomitant radiochemotherapy with carboplatin. The carboplatin was infused over 24 h with a volumetric infusion pump at the daily dose of 30 mg/m2 for 14 consecutive days (total dose, 420 mg/m2).
All subjects had normal liver and renal function, as defined by serum activities of We studied the changes of basal values of creatinine and enzymatic activities and considered significant only changes >30%, taking into account both the day of the maximal increase and the trend. We observed three different kinds of response (Table 1) :
Group A-S of 21(24%) patients presented no significant variations of tubular enzymes or of urinary creatinine. All these patients showed a low clinical tox- Group B-o of 21(28%) patients presented an early increase of tubular enzymes by day 3 of treatment without a concomitant significant variation of urinary creatinine.
Five of these patients showed a grade 1 myelotoxicity; one patient had a grade 3; only one showed Group C-b of2l (48%) patients presented a late increase of GGT and NAG
